Business Description
Vaxcyte Inc
NAICS : 541713
SIC : 2834
ISIN : US92243G1085
Share Class Description:
PCVX: Ordinary SharesDescription
Vaxcyte Inc is a vaccine company seeking to improve global health by developing novel vaccines to treat patients suffering from the most common and deadly diseases. Its product comprises. of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-24, VAX-A1, and VAX-PG.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 36.96 | |||||
| Equity-to-Asset | 0.88 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.07 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -10.7 | |||||
| 3-Year EPS without NRI Growth Rate | -4.4 | |||||
| 3-Year FCF Growth Rate | -32.4 | |||||
| 3-Year Book Growth Rate | 24.3 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 41.56 | |||||
| 9-Day RSI | 37.62 | |||||
| 14-Day RSI | 37.65 | |||||
| 6-1 Month Momentum % | 39.67 | |||||
| 12-1 Month Momentum % | 60.52 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.54 | |||||
| Quick Ratio | 7.54 | |||||
| Cash Ratio | 7.43 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -23.1 | |||||
| Shareholder Yield % | -9.72 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -33.66 | |||||
| ROA % | -31.32 | |||||
| ROIC % | -195.58 | |||||
| ROC (Joel Greenblatt) % | -752.42 | |||||
| ROCE % | -34.15 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 4.67 | |||||
| Price-to-Tangible-Book | 4.67 | |||||
| EV-to-EBIT | -13.29 | |||||
| EV-to-EBITDA | -13.63 | |||||
| EV-to-FCF | -15.03 | |||||
| Price-to-Net-Current-Asset-Value | 6.23 | |||||
| Price-to-Net-Cash | 6.34 | |||||
| Earnings Yield (Greenblatt) % | -7.52 | |||||
| FCF Yield % | -5.52 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:PCVX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Vaxcyte Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -4.752 | ||
| Beta | 1.08 | ||
| Volatility % | 32.46 | ||
| 14-Day RSI | 37.65 | ||
| 14-Day ATR ($) | 2.140619 | ||
| 20-Day SMA ($) | 62.6765 | ||
| 12-1 Month Momentum % | 60.52 | ||
| 52-Week Range ($) | 41.6 - 82.04 | ||
| Shares Outstanding (Mil) | 108.76 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Vaxcyte Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Vaxcyte Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Vaxcyte Inc Frequently Asked Questions
What is Vaxcyte Inc(PCVX)'s stock price today?
The current price of PCVX is $60.72. The 52 week high of PCVX is $82.04 and 52 week low is $41.60.
When is next earnings date of Vaxcyte Inc(PCVX)?
The next earnings date of Vaxcyte Inc(PCVX) is 2024-05-08 Est..
Does Vaxcyte Inc(PCVX) pay dividends? If so, how much?
Vaxcyte Inc(PCVX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers